CoChat

Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome

Open access
Piippo, Niina, Korhonen, Eveliina, Hytti, Maria, Skottman, Heli, Kinnunen, Kati, Josifovska, Natasha, Petrovski, Goran, Kaarniranta, Kai, Kauppinen, Anu · 2018 · Scientific Reports
Cited by 102

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Once activated, the intracellular receptor NLRP3 assembles an inflammasome protein complex that facilitates the caspase-1-mediated maturation of IL-1β and IL-18. Inactive NLRP3 is guarded by a protein complex containing Hsp90. In response to stress stimuli, Hsp90 is released, and NLRP3 can be activated to promote inflammation. In this study, we blocked Hsp90 with geldanamycin and studied the fate of NLRP3 in human retinal pigment epithelial (RPE) cells. RPE cells play a central role in the development of age-related macular degeneration (AMD), a progressive eye disease causing severe vision loss in the elderly. IL-1α-primed ARPE-19 cells, human embryonal stem cell (hESC)-derived RPE cells, and primary human RPE cells were exposed to MG-132 and bafilomycin A to activate NLRP3 via the inhibition of proteasomes and autophagy, respectively. Additionally, RPE cells were treated with geldanamycin at different time points and the levels of NLRP3 and IL-1β were determined. Caspase-1 activity was measured using a commercial assay. Geldanamycin prevented the activation of the inflammasome in human RPE cells. NLRP3 released from its protective complex became degraded by autophagy or secreted from the cells. Controlled destruction of NLRP3 is a potential way to regulate the inflammation associated with chronic diseases, such as AMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-018-25123-2

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 43

  1. Tseng, W. A. et al. NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 54, 110–120 (2013). · DOI · Paper page
  2. Petrovski, G. et al. Phagocytosis of cells dying through autophagy induces inflammasome activation and IL-1beta release in human macrophages. Autophagy 7, 321–330 (2011). · DOI
  3. Ayna, G. et al. ATP release from dying autophagic cells and their phagocytosis are crucial for inflammasome activation in macrophages. PLoS One 7, e40069 (2012). · DOI · Paper page
  4. Celkova, L., Doyle, S. L. & Campbell, M. NLRP3 Inflammasome and Pathobiology in AMD. J. Clin. Med. 4, 172–192 (2015). · DOI · Paper page
  5. Kauppinen, A., Paterno, J. J., Blasiak, J., Salminen, A. & Kaarniranta, K. Inflammation and its role in age-related macular degeneration. Cell Mol. Life Sci. 73, 1765–1786 (2016). · DOI · Paper page
  6. Wong, W. L. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health. 2, e106–16 (2014). · DOI · Paper page
  7. Velez-Montoya, R. et al. Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and prevention. Retina 34, 423–441 (2014). · DOI
  8. Buschini, E. et al. Recent developments in the management of dry age-related macular degeneration. Clin. Ophthalmol. 9, 563–574 (2015). · DOI · Paper page
  9. Mayor, A., Martinon, F., De Smedt, T., Petrilli, V. & Tschopp, J. A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nat. Immunol. 8, 497–503 (2007). · DOI · Paper page
  10. Martinon, F. Detection of immune danger signals by NALP3. J. Leukoc. Biol. 83, 507–511 (2008). · DOI · Paper page
  11. Piippo, N. et al. Decline in cellular clearance systems induces inflammasome signaling in human ARPE-19 cells. Biochim. Biophys. Acta 1843, 3038–3046 (2014). · DOI
  12. Skottman, H. Derivation and characterization of three new human embryonic stem cell lines in Finland. In Vitro Cell. Dev. Biol. Anim. 46, 206–209 (2010). · DOI
  13. Vaajasaari, H. et al. Toward the defined and xeno-free differentiation of functional human pluripotent stem cell-derived retinal pigment epithelial cells. Mol. Vis. 17, 558–575 (2011).
  14. Szatmari-Toth, M. et al. Clearance of autophagy-associated dying retinal pigment epithelial cells - a possible source for inflammation in age-related macular degeneration. Cell. Death Dis. 7, e2367 (2016). · DOI · Paper page
  15. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254 (1976). · DOI · Paper page
  16. Curtis, M. J. et al. Experimental design and analysis and their reporting: new guidance for publication in BJP. Br. J. Pharmacol. 172, 3461–3471 (2015). · DOI · Paper page
  17. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10, 417–426 (2002). · DOI · Paper page
  18. Mariathasan, S. et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213–218 (2004). · DOI · Paper page
  19. Martinon, F. & Tschopp, J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117, 561–574 (2004). · DOI · Paper page
  20. Keller, M., Ruegg, A., Werner, S. & Beer, H. D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818–831 (2008). · DOI · Paper page
  21. Doyle, S. L. et al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat. Med. 18, 791–798 (2012). · DOI · Paper page
  22. Kauppinen, A. et al. Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells–implications for age-related macular degeneration (AMD). Immunol. Lett. 147, 29–33 (2012). · DOI · Paper page
  23. Shi, G. et al. Inflammasomes Induced by 7-Ketocholesterol and Other Stimuli in RPE and in Bone Marrow-Derived Cells Differ Markedly in Their Production of IL-1beta and IL-18. Invest. Ophthalmol. Vis. Sci. 56, 1658–1664 (2015). · DOI
  24. Lamark, T. & Johansen, T. Aggrephagy: selective disposal of protein aggregates by macroautophagy. Int. J. Cell. Biol. 2012, 736905 (2012). · DOI · Paper page
  25. Park, J. W. et al. Differential expression of heat shock protein mRNAs under in vivo glutathione depletion in the mouse retina. Neurosci. Lett. 413, 260–264 (2007). · DOI
  26. Harris, H. & Rubinsztein, D. C. Control of autophagy as a therapy for neurodegenerative disease. Nat. Rev. Neurol. 8, 108–117 (2011). · DOI · Paper page
  27. Li, Y. et al. Alterations of activity and intracellular distribution of the 20S proteasome in ageing retinal pigment epithelial cells. Exp. Gerontol. 43, 1114–1122 (2008). · DOI
  28. Jung, T., Catalgol, B. & Grune, T. The proteasomal system. Mol. Aspects Med. 30, 191–296 (2009). · DOI · Paper page
  29. Kinnunen, K., Petrovski, G., Moe, M. C., Berta, A. & Kaarniranta, K. Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol. 90, 299–309 (2012). · DOI · Paper page
  30. Carman, A., Kishinevsky, S., Koren, J. 3rd, Lou, W. & Chiosis, G. Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention. J. Alzheimers Dis. Parkinsonism 2013, 007 (2013).
  31. Qin, S. et al. Inhibition of RPE cell sterile inflammatory responses and endotoxin-induced uveitis by a cell-impermeable HSP90 inhibitor. Exp. Eye Res. 93, 889–897 (2011). · DOI
  32. Kaarniranta, K. et al. Geldanamycin activates Hsp70 response and attenuates okadaic acid-induced cytotoxicity in human retinal pigment epithelial cells. Brain Res. Mol. Brain Res. 137, 126–131 (2005). · DOI
  33. Wu, W. C., Kao, Y. H., Hu, P. S. & Chen, J. H. Geldanamycin, a HSP90 inhibitor, attenuates the hypoxia-induced vascular endothelial growth factor expression in retinal pigment epithelium cells in vitro. Exp. Eye Res. 85, 721–731 (2007). · DOI
  34. Wang, Y. Q., Zhang, X. M., Wang, X. D., Wang, B. J. & Wang, W. 17-AAG, a Hsp90 inhibitor, attenuates the hypoxia-induced expression of SDF-1alpha and ILK in mouse RPE cells. Mol. Biol. Rep. 37, 1203–1209 (2010). · DOI
  35. Ryhanen, T. et al. Influence of Hsp90 and HDAC inhibition and tubulin acetylation on perinuclear protein aggregation in human retinal pigment epithelial cells. J. Biomed. Biotechnol. 2011, 798052 (2011). · DOI
  36. Poulaki, V. et al. Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J. 21, 2113–2123 (2007). · DOI
  37. Tam, L. C. et al. Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90). Hum. Mol. Genet. 19, 4421–4436 (2010). · DOI
  38. Aguila, M. et al. Hsp90 inhibition protects against inherited retinal degeneration. Hum. Mol. Genet. 23, 2164–2175 (2014). · DOI
  39. Kummar, S. et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur. J. Cancer 46, 340–347 (2010). · DOI · Paper page
  40. Pacey, S. et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin. Cancer Res. 17, 1561–1570 (2011). · DOI · Paper page
  41. Sessa, C. et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin. Cancer Res. 19, 3671–3680 (2013). · DOI · Paper page
  42. Shapiro, G. I. et al. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors. Clin. Cancer Res. 21, 87–97 (2015). · DOI
  43. Ohkubo, S. et al. TAS-116, a highly selective inhibitor of heat shock protein 90alpha and beta, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models. Mol. Cancer. Ther. 14, 14–22 (2015). · DOI · Paper page

Cited by

See all 102

Metadata

Authors
Piippo, N., Korhonen, E., Hytti, M., Skottman, H., Kinnunen, K., Josifovska, N., Petrovski, G., Kaarniranta, K., & Kauppinen, A.
Venue
Scientific Reports
Published
2018-04-30
Volume
8
Issue
1
Pages
6720-6720
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2799712672
Cited by
102
References
12
FWCI
2.67
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome. https://app.cochat.ai/papers/10.1038/s41598-018-25123-2
The paper
Piippo, N., Korhonen, E., Hytti, M., Skottman, H., Kinnunen, K., Josifovska, N., Petrovski, G., Kaarniranta, K., & Kauppinen, A. (2018). Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome. Scientific Reports. https://doi.org/10.1038/s41598-018-25123-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.